https://orcid.org/0000-0003-3096-1788
Overview
While striving to provide excellent clinical care, I also have several research interests:
1. Establish novel diagnostic biomarkers along with new therapeutic targets in Alzheimer's Disease (AD) and comorbid Cerebral Amyloid Angiopathy. I currently serve as the Associate Biomarker Core lead in the Duke-UNC Alzheimer's Disease Research Center (ADRC). I am also the site Principal Investigator (PI) of a Biogen sponsored phase 2 clinical trial, CELIA (BIIB080), that targets AD-related tau through an Anti-sense oligonucleotide (ASO) mechanism. Additionally, I am the site PI of the ALNYLAM sponsored phase 2 clinical trial. This trial knocks down the expression of APP through an ASO mechanism to potentially treat Cerebral Amyloid Angiopathy (CAA).
2. Investigate a neurodevelopmental disorder, Tuberous Sclerosis Complex (TSC), which has the potential to provide insight into the pathophysiological mechanism of AD-related tau. I have published several papers on this subject and am currently the PI of the Ann B. Bussell award that is following TSC patients longitudinally to determine if TSC is an AD-related tauopathy.
3. I am interested discovering new biomarkers to diagnose various neurodegenerative diseases. I am a co-Investigator with NCCU colleagues. We have published several new tau epitopes as potential biomarkers in diagnosing AD at earlier stages and have applied for several government funding mechanisms to continue this work.
1. Establish novel diagnostic biomarkers along with new therapeutic targets in Alzheimer's Disease (AD) and comorbid Cerebral Amyloid Angiopathy. I currently serve as the Associate Biomarker Core lead in the Duke-UNC Alzheimer's Disease Research Center (ADRC). I am also the site Principal Investigator (PI) of a Biogen sponsored phase 2 clinical trial, CELIA (BIIB080), that targets AD-related tau through an Anti-sense oligonucleotide (ASO) mechanism. Additionally, I am the site PI of the ALNYLAM sponsored phase 2 clinical trial. This trial knocks down the expression of APP through an ASO mechanism to potentially treat Cerebral Amyloid Angiopathy (CAA).
2. Investigate a neurodevelopmental disorder, Tuberous Sclerosis Complex (TSC), which has the potential to provide insight into the pathophysiological mechanism of AD-related tau. I have published several papers on this subject and am currently the PI of the Ann B. Bussell award that is following TSC patients longitudinally to determine if TSC is an AD-related tauopathy.
3. I am interested discovering new biomarkers to diagnose various neurodegenerative diseases. I am a co-Investigator with NCCU colleagues. We have published several new tau epitopes as potential biomarkers in diagnosing AD at earlier stages and have applied for several government funding mechanisms to continue this work.
Current Appointments & Affiliations
Associate Professor of Neurology
·
2024 - Present
Neurology, Behavioral Neurology,
Neurology
Associate Professor in Pathology
·
2024 - Present
Pathology,
Clinical Science Departments
Recent Publications
Artificial Intelligence-Assisted Detection of Amyloid-Related Imaging Abnormalities: Promise and Pitfalls.
Journal Article AJNR Am J Neuroradiol · February 3, 2026 The advent of anti-amyloid therapies (AATs) for Alzheimer disease (AD) has elevated the importance of MRI surveillance for amyloid-related imaging abnormalities (ARIA) such as microhemorrhages and siderosis (ARIA-H) and edema (ARIA-E). We report a literatu ... Full text Link to item CiteDiagnosing and treating catatonia in low- and middle-income countries - a scoping review.
Journal Article Compr Psychiatry · February 2026 Catatonia is a common neuropsychiatric condition in in- and outpatient settings that can be life-threatening if not diagnosed and treated promptly. Over the last few decades, our understanding of catatonia has significantly evolved. Where, how, and in whic ... Full text Link to item CiteCutaneous Phosphorylated Alpha-Synuclein in Lewy Body Dementia.
Journal Article Ann Clin Transl Neurol · December 25, 2025 OBJECTIVE: To determine the test performance of cutaneous phosphorylated alpha-synuclein (P-SYN) in dementia with Lewy bodies (DLB), individuals with reduced Montreal Cognitive Assessment (MoCA) and healthy controls. METHODS: This is the first subgroup ana ... Full text Link to item CiteRecent Grants
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA)
Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2025 - 2030Automated High-purity Exosome isolation-based AD diagnostics system (AHEADx)
ResearchCo-Principal Investigator · Awarded by National Institute on Aging · 2023 - 2028A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer¿s Disease o
Clinical TrialPrincipal Investigator · Awarded by Biogen MA, Inc. · 2023 - 2027View All Grants
Recent Artistic Works
Real World Implicatinos of Lecanemab Use
Digital Media April 29, 2025 https://www.alzforum.org/news/conference-coverage/leqembi-clinic-early-reports-aria-rates-echo-trialsSpinal Tap procedure
Digital Media April 1, 2022View All Artistic Works
Education
Rosalind Franklin University of Medicine and Science, Chicago Medical School ·
2013
M.D.
Rosalind Franklin University of Medicine and Science ·
2008
M.S.